{"filing":{"accession_number":"0001171843-26-006202","cik":"0001421642","ticker":"MSLE","company_name":"Satellos Bioscience Inc.","form":"6-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"f6k_092326.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1421642/000117184326006202/f6k_092326.htm"},"events":[{"id":34715,"run_id":31960,"accession_number":"0001171843-26-006202","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces FDA clearance of an IND application for forazapadin in a second disease indication (FSHD), expansion of clinical development into a new patient population, and a partnership with FSHD Canada Foundation providing up to US$5 million in non-dilutive financing. While the IND clearance is a regulatory milestone and the financing arrangement is material, the disclosure does not fit neatly into the specific event categories (not an earnings release, M\u0026A activity, debt issuance, or dilutive equity offering). This is a material operational and strategic milestone—expansion of a drug candidate into a new indication with secured funding—that would affect a reasonable investor's assessment of the company's pipeline and capital position.","company_name":"Satellos Bioscience Inc.","ticker":"MSLE","filing_date":"2026-09-24","form":"6-K","submitted_at":null,"items":[{"id":38535,"accession_number":"0001171843-26-006202","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA clearance of an IND application for forazapadin in a second disease indication (FSHD), expansion of clinical development into a new patient population, and a partnership with FSHD Canada Foundation providing up to US$5 million in non-dilutive financing. While the IND clearance is a regulatory milestone and the financing arrangement is material, the disclosure does not fit neatly into the specific event categories (not an earnings release, M\u0026A activity, debt issuance, or dilutive equity offering). This is a material operational and strategic milestone—expansion of a drug candidate into a new indication with secured funding—that would affect a reasonable investor's assessment of the company's pipeline and capital position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-24T11:39:56.447549+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38535,"accession_number":"0001171843-26-006202","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA clearance of an IND application for forazapadin in a second disease indication (FSHD), expansion of clinical development into a new patient population, and a partnership with FSHD Canada Foundation providing up to US$5 million in non-dilutive financing. While the IND clearance is a regulatory milestone and the financing arrangement is material, the disclosure does not fit neatly into the specific event categories (not an earnings release, M\u0026A activity, debt issuance, or dilutive equity offering). This is a material operational and strategic milestone—expansion of a drug candidate into a new indication with secured funding—that would affect a reasonable investor's assessment of the company's pipeline and capital position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-24T11:39:56.447549+00:00","company_name":"Satellos Bioscience Inc.","ticker":"MSLE","filing_date":"2026-09-24"}]}